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Abstract
Background: Cognitive behavior therapy for psychosis (CBTp) is an effective intervention for people who hear
distressing voices (auditory hallucinations). However, there continues to be a problem of poor access to CBTp.
Constraints on health care funding require this problem to be addressed without a substantial increase in funding.
One solution is to develop guided self-help forms of CBTp to improve access, and a symptom-specific focus on, for
example, distressing voices (auditory verbal hallucinations) has the potential to enhance effectiveness. We term this
cognitive behavior therapy for distressing voices (CBTv).
Methods/design: This trial is an external pilot randomized controlled trial comparing the effects of 12-week guided
self-help CBTv (with eight therapist support sessions) with a wait list control condition. Informed consent will be
obtained from each participant. Half of the 30 participants will be randomized to receive guided self-help CBTv
immediately; the remaining half will receive the intervention after a 12-week delay. All participants will continue
with their usual treatment throughout the study. Outcomes will be assessed using questionnaires completed at
baseline and 12 weeks postrandomization. Interviews will be offered to all those who receive therapy immediately
to explore their experiences with the intervention.
Discussion: The outcomes of this trial, both quantitative and qualitative, will inform the design of a definitive
randomized controlled trial of guided self-help CBTv. If this intervention is effective, it could help to increase access
to CBT for those who hear distressing voices.
Trial registration: ISRCTN registration number ISRCTN77762753. Registered on 23 July 2015.
Keywords: Voices, Auditory hallucinations, Psychosis, Cognitive behavioral therapy, CBT, Low intensity, Self-help
Background
Hearing voices (i.e., auditory verbal hallucinations) is a
common experience [1]; some people find this experience
very distressing and hear voices in the context of a mental
health problem [2]. Hearing distressing voices is a symp-
tom of psychotic spectrum disorders, such as schizophre-
nia [3], but voices can also be present in the context of
other mental health conditions, such as borderline
personality disorder [4], dissociative identity disorder [5],
bipolar disorder [6], and posttraumatic stress disorder [7].
The authors of a meta-analysis found cognitive behav-
ioral therapy for psychosis (CBTp) to be an effective
treatment for distressing voices [8]. National treatment
guidelines issued in a number of countries recommend
that everyone with a psychotic disorder be offered CBTp
[9–11], with the guidelines stating that at least 16 indi-
vidual sessions of CBTp should be offered.
Despite evidence for its effectiveness and recommen-
dations in national treatment guidelines, CBTp is not
widely available. Even though the United Kingdom has
led the way in promoting the implementation of CBTp
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[12], the authors of a report by the U.K. Schizophrenia
Commission [13] found only 10 % of people with psych-
osis were offered CBTp. More recent figures suggest this
rate may have actually decreased [14].
The most consistently reported barrier to implementation
is insufficient resources to meet the demand, including both
insufficient numbers of therapists trained in providing
CBTp [15] and trained therapists’ lack of protected time
[14]. The current economic climate has had a deleterious
impact on mental health funding across the globe [16].
Consequently, it is not realistic to expect that resources re-
quired to deliver CBTp in line with treatment guidelines
will be available in the near future. An alternative approach
is to use available resources more efficiently. This could in-
clude offering CBTp self-help resources with a therapist’s
guidance, an approach that requires less therapist resources
than standard interventions [17]. We propose a guided self-
help form of CBTp that could be a suitable intervention for
this client group. Our approach requires less therapeutic
contact time (8 sessions) than the recommended 16 ses-
sions, so the same number of therapists could, in principle,
offer an intervention to twice as many people over the
course of a year.
The authors of multiple meta-analyses have found that
guided self-help cognitive behavioral therapy (CBT) is ef-
fective for treatment of anxiety and depression [18, 19],
and, as a consequence, guided self-help CBT is offered
routinely in the United Kingdom for people experiencing
these difficulties [20]. Evidence is emerging that briefer
forms of CBTp may also be effective. A meta-analysis
found that, in comparison to control conditions, briefer
forms of CBTp (i.e., trials offering fewer than the recom-
mended 16 therapy sessions) significantly improved
psychosis symptoms at posttherapy and during follow-up
[21]. However, the authors of a previous meta-analysis of
CBTp more broadly showed that trial quality is an import-
ant moderator of treatment effects; with high-quality
CBTp trials producing smaller effect sizes than lower-
quality trials [22, 23]. Therefore, lower-quality trials may
overestimate the effectiveness of briefer forms of CBTp.
In addition, in an effort to improve the effectiveness of
CBTp, the field is moving away from generic CBTp for
the broad range of psychotic symptoms and toward
symptom-specific CBTp, with recent trials being focused
on CBTp for delusions [24] and distressing voices [25].
However, to our knowledge, there has been no research
into the potential of guided self-help for distressing
voices, and this is the aim of the present study.
This study is an external pilot randomized controlled
trial (RCT) being conducted prior to a definitive trial of
guided self-help CBTp for people distressed by hearing
voices (which we term CBTv). Guided self-help CBTv aims
to reduce the distress associated with the experience of
hearing voices. Therefore, the primary hypothesis for the
trial will be that, compared with the delayed therapy con-
trol group, those who receive guided self-help CBTv will
experience a reduction in the distress associated with
voices. Secondary hypotheses will be that those receiving
guided self-help CBTv will report improvement in nega-
tive and positive beliefs about voices, self-esteem, and as-
sertive relating in comparison with the control group,
which are the mechanisms through which the therapy is
proposed to work [26].
The following are the aims of the present pilot study: (1)
to determine whether a full trial is justified, (2) to establish
the effect size on the primary outcome (voice-related
distress) for a sample size calculation for a definitive trial,
and (3) to address questions concerning study recruitment,
retention, and acceptability. Specifically, between-group
treatment effects will determine whether a definitive RCT
of guided self-help CBTv is justified; that is, we will proceed
if the effect size on the primary outcome is in favor of CBTv
in comparison to the delayed therapy control condition and
if the 95 % CI for this effect contains the minimal clinically
important difference (MCID). If so, this study will provide
the parameters needed to estimate the sample size for a
definitive RCT. Finally, we will assess whether the study
design is acceptable to participants using recruitment and
retention rates and qualitative interviews with participants.
Both study dropout and therapy dropout rates will be re-
ported with a view to understanding reasons for dropout
and developing strategies to minimize dropout in a defini-
tive trial.
Methods/design
This study is a pragmatic, single-blind, external pilot
RCT with two parallel arms and 1:1 allocation. A
rater blinded to allocation will conduct postinterven-
tion assessments. A total of 30 participants will be
recruited; half will be randomly allocated to receive
guided self-help CBTv immediately (immediate ther-
apy), and half will join a wait list for the same inter-
vention (delayed therapy). Both groups will maintain
their usual mental health care throughout the course
of the study.
The randomization of participants will be conducted by
an independent statistician, using a 1:1 ratio random per-
muted block randomization (with block sizes of two, four,
and six). The research team will be blinded to the block
size. Figure 1 illustrates the process of randomization and
group allocation.
The outcome data will be collected at time 0 (before
randomization), and at time 1 (12 weeks postrandomiza-
tion). Time 1 assessments will be conducted by a research
assistant blinded to the participant’s group allocation. All
of the participants allocated to receive immediate therapy
will be asked to complete an exit interview to discuss their
experience with the therapy.
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To assess adherence to the protocol, all therapists will
be asked to complete a checklist after each session with
each client, indicating the elements of the protocol they
have covered. The checklist has been designed specific-
ally for this intervention.
Participants
Participants will be service users recruited from an NHS
mental health trust in the South of England. Clinicians
will be asked to refer eligible service users from among
their caseload. Potential participants will also be identi-
fied using a database of people who have agreed to be
contacted about research studies.
In line with the recommendations of Julious [27] for
pilot RCTs, 12 participants per arm are required for this
pilot RCT. The authors of a meta-analysis of briefer
forms of CBTp found the maximum dropout rate to be
13.5 % [21]. Using this as a guideline, we have overesti-
mated a potential attrition rate of 20 % for the present
study, meaning a total of 30 participants will be re-
cruited (15 per arm).
The inclusion criteria for participants are that they
must (1) be aged 18 years or older; (2) be distressed by
hearing voices; which will be operationalized by requir-
ing participants to score at least 3 out of 5 on item 5
(How much do the voices interfere with your daily activ-
ities?), 6 (How distressing are the voices that you hear?),
or 7 (How bad do the voices make you feel about your-
self ) on the Hamilton Program for Schizophrenic Voices
Questionnaire (HPSVQ) [28], equivalent to moderate
levels of interference, distress, and impact, respectively;
(3) have heard voices for the at least 1 year; (4) are not
currently in, or have plans to receive, another psycho-
logical intervention during the course of the study; and
(5) are able to read and write in English at the level re-
quired for the self-help course.
Participants will be excluded from the trial if they have
a primary diagnosis of substance misuse or if an organic
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) diagram of participant progression through the Guided self-help cognitive behavioral
intervention for VoicEs trial. CBTv cognitive behavioral therapy for voices, TAU treatment as usual
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illness is determined as the reason for hearing voices.
Otherwise, diagnosis is not an inclusion or exclusion cri-
terion, given that distressing voices are common across
a range of diagnoses (i.e., schizophrenia [3], borderline
personality disorder [4], dissociative identity disorder [5],
bipolar disorder [6], posttraumatic stress disorder [7]).
Planned intervention
The 12-week intervention is based on and guided by the
self-help book Overcoming Distressing Voices [26] and an
accompanying workbook that summarizes the key chap-
ters. The therapists and participants will have the same
therapy materials (book and workbook). Therapist guid-
ance will be offered over a maximum of 8 sessions (30–
60 minutes per session) delivered over the 12 weeks.
The intervention will be guided by clinical psychologists
with expertise in CBTp, and participants will be encour-
aged to engage with the structured self-help workbook
throughout. The intervention protocol has been devel-
oped in collaboration with clinicians and people with
lived experience of hearing voices.
The intervention consists of five modules: (1) The Cop-
ing module will look at ways of managing voice distress;
current coping strategies will be evaluated, and new ones
considered; (2) the Me module will address self-esteem;
negative beliefs about the self will be re-evaluated, and
positive beliefs will be strengthened; (3) the My Voices
module will target unhelpful beliefs that are typically asso-
ciated with voices, focusing on re-evaluating these beliefs;
(4) the My Relationships module will give the participant
an opportunity to work on a difficult relationship (includ-
ing the relationship with voices), the aim being to develop
more assertive ways of relating; and (5) the Looking to the
Future module offers an opportunity for reflection and de-
velops a plan for taking learning from the self-help course
forward into the future.
Participants will keep the book and workbook after
therapy has ended, providing a resource they can return
to at a later date. Participants will be free to drop out of
the intervention at any point. Therapists will each re-
ceive training in the intervention from CS and MH (au-
thors of the self-help book), and monthly therapist
group supervision will be offered.
Wait-list control (delayed therapy)
Participants allocated to delayed therapy will join a wait-
ing list for the intervention. The waiting period will be
approximately 12 weeks after randomization, at which
point participants will receive the intervention as out-
lined above.
Throughout the trial (including the waiting period),
participants will continue with their usual mental health
care. This will likely involve taking psychiatric medica-
tion and having regular contact with a clinician. The
type of medication participants are taking, as well as any
changes in these across the span of the study, will be
recorded.
Measures
The primary outcome will be the HPSVQ voice impact
subscale [28]. The HPSVQ voice impact subscale has five
items rated on a 5-point (0–4) scale and measures the
level of distress and impact that voices have on the person.
The phenomenology subscale (four items) will also be in-
cluded in this trial (and will be a secondary measure in the
definitive trial). The questionnaire contains nine items in
total and has strong concurrent validity (all r > 0.80) as
well as good internal consistency (all α > 0.82) [29].
The following measures of secondary outcomes are
also included in this trial:
1. The Choice of Outcome in CBT for Psychoses
questionnaire [30] was developed in partnership with
service users. It has 22 items measuring service user-
defined recovery. Two of the items give participants
the opportunity to include their own recovery goals
for CBT. The severity scale of this questionnaire has a
high level of test-retest reliability (α = 0.83).
2. The Hospital Anxiety and Depression Scale (HADS)
[31] measures clinical levels of anxiety and/or
depression. The HADS has 12 items. The English
version of this questionnaire has good internal
consistency (α = 0.80) [32].
3. The Short Warwick-Edinburgh Mental Well-being
Scale (SWEMBS) [33] uses seven items to measure
psychological well-being. The SWEMBS has demon-
strated good reliability (α = 0.91).
4. The Rosenberg Self-Esteem Scale (RSES) [34] con-
sists of ten items. It was originally developed to
measure self-esteem among adolescents, but it has
since been used with adults with strong psychomet-
ric properties. The RSES has strong levels of test-
retest reliability over time (r = 0.85).
5. The Brief Core Schema Scale (BCSS) self-scale [35]
measures participants’ endorsement of positive and
negative beliefs about themselves. The BCSS self-scale
has 12 items and has strong internal consistency when
given to clinical participants (α = 0.84).
6. The Person’s Relating to Others Questionnaire short
version (PROQ3) [36] measures social relating
(person to person) in terms of their proximity and
power. The questionnaire includes 48 items, and all
scales show acceptable levels of internal consistency
(all scales α > 0.70).
7. The Voice and You [37] measures the same
relational dimensions as the PROQ3 [36] but in the
context of the participant’s relationship with their
voices (hearer to voice). The scale has 28 items and
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demonstrates good internal consistency across all of
the scales (all scales α > 0.80).
8. The Beliefs about Voices Questionnaire–Revised
[38] has 35 items and measures the strength of a
range of beliefs about voices. All scales have
acceptable levels of internal consistency (all scales
α > 0.74).
Sessional measures will be taken using six visual analogue
scale questions, with each question targeting an intended
therapy outcome or mechanism. An exit interview will be
administered postintervention to participants in the imme-
diate therapy condition. The Change Interview [39] will be
used at that time to ask participants to consider any
changes they have experienced over the course of the inter-
vention and, if so, what they attribute these changes to.
Helpful, unhelpful, and missing aspects of the intervention
are also explored within the Change Interview. The Change
Interview also asks participants to provide feedback on
their experience with the research study itself, as well as to
provide suggestions for future research in the area. The exit
interview will also include additional questions on partici-
pants’ experiences of the study process (e.g., assessments,
consent, randomization) [40].
Data collection and storage
All data will be collected and stored in line with the
Data Protection Act (1998). Assessments will be com-
pleted using tablet computers so that data are entered
and stored electronically. Anonymized data will be
stored on password-protected computers and will be
available to members of the research team. Any files that
contain personal information of participants will be kept
in a password-protected electronic file or in locked filing
cabinets on NHS or university sites. To maximize study
retention, participants will be invited to complete postin-
tervention assessments even if they have dropped out of
the intervention, and all assessments will be conducted
at a time and place most convenient to the participant.
Planned analysis
All of the analyses will be carried out once data collec-
tion has been completed. IBM SPSS Statistics version 22
software (IBM, Armonk, NY, USA) will be used to con-
duct all quantitative analyses. The findings of this trial
will be reported using the Consolidated Standards of
Reporting Trials (CONSORT) guidelines. The recruit-
ment rates for this trial will be reported as a ratio of the
number of potential participants approached to the
number who consent to participate. The retention rates
will be reported first as the percentage of participants
who drop out of the study (i.e., do not complete time 1
assessments) and second as the percentage of partici-
pants who drop out of therapy before exposure (receive
fewer than four sessions). If study or therapy dropout
rates are greater than 33 %, this will indicate that
changes to the study and/or therapy protocols may be
needed. The acceptability of the study and therapy will
be assessed using retention rates and feedback obtained
through the exit interview.
The analysis for this trial will be mostly descriptive.
We will report the means and/or medians (as appropri-
ate) as well as SD and minimum and maximum scores
at time 0 and time 1 for both groups on primary and
secondary outcomes. Participants’ characteristics will be
reported using frequency counts and percentages, in-
cluding the characteristics of any participants who drop
out of the study and/or therapy. Analysis of covariance
will be used to estimate T1 between-group differences
on primary and secondary measures, controlling for
baseline scores. Ninety-five percent confidence intervals
will be calculated. Effect sizes will be reported as Cohen’s
d (unstandardized effect size divided by the baseline
pooled SD). We will look at the effect sizes using both an
intention-to-treat analysis approach and a per-protocol
analysis (looking only at participants who attended at least
50 % of therapy sessions). A definitive trial will be consid-
ered to be justified if there is a between-group effect in
favor of CBTv on the primary outcome (HPSVQ voice im-
pact subscale [28]) and if the 95 % CI contains the MCID
of 2 points in favor of CBTv.
The exit interviews will be transcribed into NVivo soft-
ware files (QSR International, Doncaster, Australia) and
analyzed using thematic analysis in accordance with the
Braun and Clarke [41] protocol. The aim of the analysis
will be to identify common patterns across interviews that
reflect the participants’ experiences of therapy and of the
study processes. These themes, as well as the quantitative
results, will be used to refine the study and therapy proto-
cols. If a definitive trial is justified, then the power calcula-
tions will be based upon the between-groups effect size on
the HPSVQ voice impact subscale [28].
Research governance
This protocol has been prepared in line with the Stand-
ard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) guidelines [42, 43]. See Fig. 2 and add-
itional material for a copy of the SPIRIT figure and
checklist for this study.
The trial is sponsored by the University of Sussex and
funded through a doctoral studentship award given to
CMH by the Economic Social and Research Council
(ES/J500173/1) and Sussex Partnership NHS Founda-
tion Trust. Ethics approval has been granted by the
NHS Health Research Authority North West – Lancas-
ter Research Ethics Committee (REC) (15/NW/0575).
Written informed consent will be obtained from each
participant by the lead author. A copy of the participant
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information sheet and consent form can be obtained
from the corresponding author.
A Trial Steering Committee (TSC) will be established
in accordance with Medical Research Council guidelines
[44] and will monitor the conduct of the trial and adher-
ence to the study protocol. The TSC will include an in-
dependent chair, independent experts, and lay members.
If necessary, applications to make significant protocol
amendments will be made to the REC and study spon-
sor. A Data Monitoring Committee is not deemed ne-
cessary, given the pilot nature of the current study.
The U.K. National Institute of Health Research Good
Clinical Practice guidelines will be followed, which in-
cludes reporting and investigation of any adverse events
during the study. In line with these guidelines, the re-
search team will ensure that the patient care team mem-
bers are aware of any adverse events. If an adverse event
is deemed to be related to the study, it will be reported
to the study sponsor. The sponsor will then determine
whether the study needs to be stopped and if an investi-
gation of the adverse event is needed.
Dissemination
Findings will be written up for publication in an open-
access, peer-reviewed journal, and a lay summary of
findings will be sent to all study participants.
Discussion
The development of guided self-help CBTv is one
approach that could potentially address the problem
of limited access to CBT in the United Kingdom for
people who experience psychosis [45]. However, it
would be inadvisable to offer guided self-help CBTv
routinely, as we do not yet know if it is acceptable
or effective at reducing voice-related distress; it is an
approach that widens access but that, if ineffective,
would be of little use and a waste of limited
resources.
This external pilot RCT will generate effect sizes of
CBTv in comparison to the wait-list control group on the
primary outcome (voice-related distress) and on second-
ary measures. The trial results will also indicate recruit-
ment and retention rates and intervention acceptability.
These parameters will inform the design and sample size
calculation for a definitive trial. If found to be effective
within a definitive trial, guided self-help CBTv has the po-
tential to widen access to an effective, evidence-based
intervention for people distressed by hearing voices.
Trial status
The trial has received ethical and governance approvals.
Recruitment began in September 2015 and is planned to
end in January 2016.
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